TY - JOUR
T1 - Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma
AU - Van Praet, Charles
AU - Slots, Charlotte
AU - Vasdev, Nikhil
AU - Rottey, Sylvie
AU - Fonteyne, Valérie
AU - Andras, Iulia
AU - Albersen, Maarten
AU - De Meerleer, Gert
AU - Bex, Axel
AU - Decaestecker, Karel
PY - 2021/1/25
Y1 - 2021/1/25
N2 - Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.
AB - Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.
M3 - Article
JO - Turkish Journal of Urology
JF - Turkish Journal of Urology
SN - 2149-3057
ER -